Terms: = Ovarian cancer AND BRD3, KIAA0043, 8019, ENSG00000169925, Q15059, ORFX, RING3L
4 results:
1. Targeting BET Proteins BRD2 and brd3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for ovarian Clear Cell Carcinoma.
Shigeta S; Lui GYL; Shaw R; Moser R; Gurley KE; Durenberger G; Rosati R; Diaz RL; Ince TA; Swisher EM; Grandori C; Kemp CJ
Mol Cancer Ther; 2021 Apr; 20(4):691-703. PubMed ID: 33509905
[TBL] [Abstract] [Full Text] [Related]
2. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
[TBL] [Abstract] [Full Text] [Related]
3. NUT midline carcinoma presenting with bilateral ovarian metastases: a case report.
Dragoescu E; French C; Cassano A; Baker S; Chafe W
Int J Gynecol Pathol; 2015 Mar; 34(2):136-42. PubMed ID: 25675182
[TBL] [Abstract] [Full Text] [Related]
4. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm.
Aktas D; Guney I; Alikasifoglu M; Yüce K; Tuncbilek E; Ayhan A
Gynecol Oncol; 2002 Aug; 86(2):124-8. PubMed ID: 12144816
[TBL] [Abstract] [Full Text] [Related]
